ETHERNIALongevity drugsFrontier
Rapamycin: the strongest mouse story is still a human question.
mTOR inhibition, the PEARL results and a 2026 exercise trial that complicates the story.
Interventions
Find the question that matters.
Explore the disciplines behind longevity interventions, then read the claim and the evidence together.
5 dossiers
Longevity drugs ↓
mTOR, senescent cells and the difficult translation from mechanism to medicine.
5 dossiersSupplements ↓
Target engagement, meaningful outcomes and the distance between them.
2 dossiersNutrition ↓
Restriction, nutrient sensing and experiments in the pace of ageing.
3 dossiersPhysical capacity ↓
Function, strength and aerobic capacity as outcomes that matter.
1 dossiersBiomarkers & diagnostics ↓
Biological clocks, predictive measurements and clinical validation.
1 dossiersRejuvenation technology ↓
Reprogramming, cellular identity and the engineering of biological repair.
Longevity drugs
Compare evidence →Longevity drugsFrontier
Senolytics: clearing damaged cells, testing a powerful idea.
Why senescent cells became a target—and why early human trials need a harder reading.
Longevity drugsFrontier
Metformin: a diabetes drug facing a much harder question.
Human molecular signals, exercise trade-offs and the unfinished test of geroprotection.
Longevity drugsFrontier
Acarbose: a strong mouse result meets a negative human endpoint.
A reproducible animal question, a large cardiovascular trial, and endpoints that must not be conflated.
Longevity drugsEstablished
GLP-1 therapies: a clinical benefit is not the same as age reversal.
A large randomized outcome trial provides a useful benchmark for longevity claims.
Supplements
Compare evidence →SupplementsFrontier
NAD precursors: raising a molecule is the beginning of the question.
NR, NMN, metabolic signals and the gap between target engagement and longevity.
SupplementsPromising
Creatine: measure the extra capacity, not the marketing.
A comparatively practical supplement question with human training data and no human lifespan result.
SupplementsFrontier
Taurine: the intervention and the biomarker are different hypotheses.
A striking animal study and a later challenge to the idea of universal taurine decline.
SupplementsFrontier
Spermidine: autophagy is a rationale, not a memory result.
The SmartAge trial tests what an attractive cellular mechanism can actually deliver.
SupplementsPromising
Urolithin A: immune-cell changes are a signal worth testing.
A 2025 randomized trial moves mitochondrial quality control into a measurable human question.
Nutrition
Compare evidence →NutritionPromising
Caloric restriction: a lifespan experiment with a human translation problem.
From controlled mouse survival experiments to CALERIE’s small, selective changes in methylation measures.
NutritionPromising
Fasting: timing, energy intake and ageing are separate variables.
A 2025 randomized trial offers a practical result without establishing a fasting-specific longevity effect.
Physical capacity
Compare evidence →Physical capacityEstablished
Physical capacity: the benchmark every longevity intervention should face.
VO₂ max, strength, frailty and why a meaningful outcome can be more revealing than a molecular score.
Physical capacityEstablished
Resistance training: preserving a reserve you can actually use.
The distinction between muscle size, strength, daily function and survival.
Physical capacityPromising
Sleep regularity: a mortality predictor is not yet a longevity treatment.
What wearable-derived timing can reveal, and why prediction does not establish causation.
Biomarkers & diagnostics
Compare evidence →BiomarkersPromising
Biological-age clocks: useful instruments, unfinished verdicts.
What methylation clocks measure, why algorithms disagree and what “five years younger” cannot tell you.
Rejuvenation technology
Compare evidence →RejuvenationFrontier
Partial reprogramming: can cells regain function without losing identity?
OSK, the eye, the first human trial and the much larger challenge of whole-body rejuvenation.